Clinical Trial Update: Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for TNG462 in combination therapy for pancreatic ductal adenocarcinoma and non-small cell lung cancer, currently recruiting in Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• TNG462

Snippet

Sponsor: Tango Therapeutics, Inc. | Conditions: PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING